Providers/Grant Support
Provided by Integrity CE, LLC.
Supported by ARS Pharmaceuticals Operations, Inc.
Credits Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity is designed for primary care, pediatric, allergy/immunology, and emergency room clinicians, as well as other healthcare providers involved in the treatment and management of anaphylaxis.
Program Overview
Despite clear guidelines calling for prompt administration of epinephrine for anaphylaxis, real-world data show continued delays, underuse of rescue therapy, and overreliance on antihistamines across primary care, pediatric, and emergency settings. Patients and caregivers frequently face barriers such as needle phobia, inconsistent device carriage, uncertainty about when epinephrine is needed, and limited awareness of newer needle-free options. Clinicians also report challenges in addressing device preferences, reinforcing timely epinephrine use, and correcting misconceptions, particularly as nasal epinephrine and other emerging therapies expand rescue options. The increasing use of preventive biologics has further contributed to confusion, with some families incorrectly assuming rescue epinephrine is no longer necessary. This program uses interactive, case-based learning to equip clinicians with practical, patient-centered strategies to improve counseling, device selection, and anaphylaxis readiness across home, school, and community settings.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Apply evidence-based communication strategies to counsel patients and caregivers on recognizing anaphylaxis and the importance of timely epinephrine administration
- Compare currently available epinephrine delivery options, including autoinjectors, nasal spray formulations, and emerging alternatives, to support patient-centered device selection based on individual preferences, needs, and clinical context
- Address common misconceptions and barriers that contribute to under-utilization of epinephrine, such as fear of needles, reliance on antihistamines, concerns about nasal congestion, and misunderstanding of the role of preventive therapies
- Develop personalized anaphylaxis readiness plans that incorporate shared decision-making, reinforce carriage and correct use of rescue medication, and ensure alignment across home, school, and community settings
Faculty
Theresa A. Bingemann, MD
Professor of Medicine and Pediatrics
Department of Medicine, Allergy/Immunology and Rheumatology
Department of Pediatrics, Pediatric Allergy/Immunology
Program Director, Allergy and Immunology Fellowship Program
University of Rochester Medical Center
Rochester, New York
Thomas B. Casale, MD
Professor of Medicine and Pediatrics
Director, Division of Allergy and Immunology
Joy McCann Culverhouse Clinical Research Center
University of South Florida
Tampa, Florida
Accreditation Statement
Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Integrity CE, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflict of Interest
Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:
Theresa A. Bingemann, MD
Consultant: Bryn, National Peanut Board, Pharming, Sanofi
Thomas B. Casale, MD
Consultant: ARS Pharmaceuticals, AstraZeneca, Eli Lilly, Excellergy, Genentech, Jasper, Novartis, Pfizer, Sanofi/Regeneron
Research: National Institutes of Health, Thermo Fisher Scientific
Royalties: UpToDate
The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this activity. During the period of April 27, 2026 through April 27, 2027, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
Certificates will be immediately available to the participant.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Contact Information
For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or [email protected].